Nexavar® India Harvard Case Solution & Analysis

IMD-3-2310 © 2012
Boscheck, Ralf

On 9 March 2012, a choice taken by India's Controller General of Patents, Hallmarks and designs restored a dragged out argument on the usage and abuse of copyright rights in global commerce. The judgment gave a non-assignable and non-exclusive required permit to Natco Pharma to produce and offer a generic variation of Bayer's Nexavar-- a substance abuse to deal with advanced-stage liver and kidney cancer.

Nexavar® India Case Study Solution

Hyderabad-based Natco would offer a month-to-month dosage of the life-saving medication for INR 8,800 ($172), i.e. at a discount rate of 97 % on the pioneer rate, and would pay 6 % royalties to Bayer. The choice was praised by NGOs and client advocacy groups, others hoped that the case would set off a much required evaluation of appropriate competitors and trade policy requirements, of the authenticity of nationwide versus business commercial policy goals, as well as of the particular functions of emerged versus emerging markets and those of states versus companies in financing research study and supplying health care. The case supplies a beginning point for that conversation.

Subjects: Intellectual property rights; Generic drugs; Competition and trade policy standards
Settings: India; Global ; Pharmaceutical ; Turnover > USD 100 million ; 2012

Other Similar Case Solutions like

Nexavar® India

Share This